Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial

The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with de novo acute myeloid leukemia (AML). Here we report an independent review of EFS,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Juliette, Pautas, Cécile, Terré, Christine, Raffoux, Emmanuel, Turlure, Pascal, Caillot, Denis, Legrand, Ollivier, Thomas, Xavier, Gardin, Claude, Gogat-Marchant, Karïn, Rubin, Stephen D., Benner, Rebecca J., Bousset, Pierre, Preudhomme, Claude, Chevret, Sylvie, Dombret, Herve, Castaigne, Sylvie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ferrata Storti Foundation 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312010/
https://www.ncbi.nlm.nih.gov/pubmed/30076173
http://dx.doi.org/10.3324/haematol.2018.188888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312010/
https://www.ncbi.nlm.nih.gov/pubmed/30076173
http://dx.doi.org/10.3324/haematol.2018.188888

Ejemplares similares